MA50413A - Dérivés de benzimidazole et leurs utilisations - Google Patents

Dérivés de benzimidazole et leurs utilisations

Info

Publication number
MA50413A
MA50413A MA050413A MA50413A MA50413A MA 50413 A MA50413 A MA 50413A MA 050413 A MA050413 A MA 050413A MA 50413 A MA50413 A MA 50413A MA 50413 A MA50413 A MA 50413A
Authority
MA
Morocco
Prior art keywords
benzimidazole derivatives
benzimidazole
derivatives
Prior art date
Application number
MA050413A
Other languages
English (en)
Inventor
Michael D Bartberger
Nagasree Chakka
Hua Gao
Angel Guzman-Perez
Daniel B Horne
Zihao Hua
Madeleine Kieffer
Daniel C H Lin
Benjamin Charles Milgram
Jane Panteleev
Laurie Schenkel
John Stellwagen
Matthew Weiss
Ryan D White
Wei Zhao
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA50413A publication Critical patent/MA50413A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA050413A 2017-10-19 2018-10-18 Dérivés de benzimidazole et leurs utilisations MA50413A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762574465P 2017-10-19 2017-10-19
US201862671090P 2018-05-14 2018-05-14

Publications (1)

Publication Number Publication Date
MA50413A true MA50413A (fr) 2020-08-26

Family

ID=66173507

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050413A MA50413A (fr) 2017-10-19 2018-10-18 Dérivés de benzimidazole et leurs utilisations

Country Status (24)

Country Link
US (1) US11332459B2 (fr)
EP (1) EP3697410B1 (fr)
JP (1) JP7450534B2 (fr)
KR (1) KR102697255B1 (fr)
CN (1) CN111417394B (fr)
AU (1) AU2018351059B2 (fr)
CA (1) CA3079081A1 (fr)
CL (1) CL2020001020A1 (fr)
CO (1) CO2020004669A2 (fr)
ES (1) ES3004333T3 (fr)
HR (1) HRP20250272T1 (fr)
HU (1) HUE070649T2 (fr)
IL (1) IL273839B (fr)
MA (1) MA50413A (fr)
MX (1) MX2020003993A (fr)
NZ (1) NZ763311A (fr)
PH (1) PH12020550265A1 (fr)
PL (1) PL3697410T3 (fr)
SA (1) SA520411787B1 (fr)
SG (1) SG11202003502VA (fr)
TW (1) TWI816704B (fr)
UY (1) UY37941A (fr)
WO (1) WO2019079578A1 (fr)
ZA (1) ZA202002762B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6899975B2 (ja) 2018-05-14 2021-07-07 ギリアード サイエンシーズ, インコーポレイテッド Mcl−1阻害剤
KR102811265B1 (ko) * 2019-04-11 2025-05-23 데이진 화-마 가부시키가이샤 벤즈이미다졸 유도체 및 이들의 용도
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
CA3294692A1 (en) 2019-11-26 2026-03-02 Gilead Sciences, Inc. Processes and intermediates for preparing mcl1 inhibitors
MX2022012923A (es) * 2020-04-16 2022-11-16 Boehringer Ingelheim Int Inhibidores de trpc6 para tratar afecciones respiratorias.
AR121846A1 (es) 2020-04-16 2022-07-13 Teijin Pharma Ltd Derivado de arilo o heteroarilo
US12202782B2 (en) 2020-11-19 2025-01-21 Gilead Sciences, Inc. Processes and intermediates for preparing MCL1 inhibitors
JPWO2023276828A1 (fr) * 2021-06-29 2023-01-05

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2618435B1 (fr) 1987-07-23 1989-10-27 Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
US5670501A (en) 1994-09-01 1997-09-23 Discovery Therapeutics, Inc. N-substituted 9-alkyladenines
AU2001277754B2 (en) 2000-08-10 2005-09-29 Mitsubishi Tanabe Pharma Corporation Proline derivatives and use thereof as drugs
CA2462374C (fr) 2001-10-15 2011-01-18 Janssen Pharmaceutica N.V. Derives de 4-phenyl-4-(1h-imidazol-2-yl)-piperidine substituee utiles pour reduire les lesions ischemiques
JP4417108B2 (ja) 2001-10-15 2010-02-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 新規な置換された4−フェニル−4−[1h−イミダゾール−2−イル]−ピペリジン誘導体および選択的非ペプチドデルタオピオイドアゴニストとしてのそれらの使用
EP1553089B1 (fr) 2002-07-30 2009-09-30 Banyu Pharmaceutical Co., Ltd. Antagoniste de recepteur d'hormone concentrant de la melanine comprenant un derive de benzimidazole en tant qu'ingredient actif
JP2006505570A (ja) 2002-10-17 2006-02-16 アムジエン・インコーポレーテツド ベンズイミダゾール誘導体およびそれのバニロイド受容体リガンドとしての使用
WO2005051949A1 (fr) 2003-11-26 2005-06-09 Dainippon Sumitomo Pharma Co., Ltd. Nouveau derive d'imidazole condense
DE102004017932A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
WO2006010283A1 (fr) 2004-07-28 2006-02-02 Universität Zürich Prevention et traitement de la formation de thrombus
US20100267717A1 (en) 2005-07-29 2010-10-21 4Sc Ag Novel Heterocyclic NF-kB Inhibitors
US7601745B2 (en) 2004-09-27 2009-10-13 4Sc Ag Heterocyclic NF-kB inhibitors
DE102005012875B4 (de) 2005-03-19 2006-11-16 Sanofi-Aventis Deutschland Gmbh Verwendung von Amino substituierten 8-N-Benzimidazolen
DE102005012874A1 (de) 2005-03-19 2006-09-21 Sanofi-Aventis Deutschland Gmbh Amid substituierte 8-N-Benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2006108089A1 (fr) * 2005-04-06 2006-10-12 North Carolina State University Articles denses et profiles construits a partir d'un materiau refractaire et procedes de preparation de ces articles
EP1739078A1 (fr) 2005-05-30 2007-01-03 Jerini AG Antagonistes du recepteur C5a
EP1951286A4 (fr) 2005-10-07 2009-11-04 Waratah Pharmaceuticals Inc Utilisation combinee d'inhibiteurs de la dpp-iv et de composes gastrine
JP2009541454A (ja) 2006-07-03 2009-11-26 ノイロサーチ アクティーゼルスカブ モノアミン再摂取阻害剤及びカリウムチャネル活性剤の併用
CA2661334C (fr) 2006-08-23 2011-11-29 Pfizer Products Inc. Composes de pyrimidone en tant qu'inhibiteurs de gsk-3
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
WO2008100977A2 (fr) 2007-02-14 2008-08-21 N.V. Organon Agents de libération thérapeutiques
WO2008153701A1 (fr) 2007-05-24 2008-12-18 Schering Corporation Composés d'inhibition de l'activité de ksp kinésine
CA2695008A1 (fr) 2007-07-30 2009-02-05 Auspex Pharmaceuticals, Inc. Indoles substitues
WO2009089234A2 (fr) 2008-01-07 2009-07-16 Auspex Pharmaceuticals Dibenzhydrylpipérazines substituées
WO2010104306A2 (fr) 2009-03-07 2010-09-16 주식회사 메디젠텍 Compositions pharmaceutiques pour traiter ou prévenir des maladies causées par la translocation de gsk3 du noyau cellulaire au cytoplasme, contenant des composés inhibant la translocation de gsk3 du noyau cellulaire au cytoplasme
PT2440231T (pt) 2009-06-10 2020-01-08 Nono Inc Co-administração de um agente ligado a um peptido de internalização tat com um inibidor de desgranulação de mastócitos
WO2011023812A1 (fr) 2009-08-27 2011-03-03 Novasaid Ab Inhibiteurs de prostaglandine e synthase-1 (mpges1) microsomale
EP2368876A1 (fr) 2010-03-01 2011-09-28 Sanofi Dérivés d'aminoindanes, leur préparation et leur application en thérapeutique
EP2651405A2 (fr) 2010-12-14 2013-10-23 Electrophoretics Limited Inhibiteurs de caséine kinase 1 (ck1 )
WO2012098281A2 (fr) 2011-01-19 2012-07-26 Universidad Miguel Hernández De Elche Peptides modulateurs de récepteurs trp et leurs utilisations
CA2828456C (fr) 2011-03-03 2021-05-04 Zalicus Pharmaceuticals Ltd. Inhibiteurs n-benzyl-amino-carboxamide du canal sodique
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
EP2698367A1 (fr) 2012-08-14 2014-02-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Benzimidazoles pour le traitement du cancer
GB201223265D0 (en) 2012-12-21 2013-02-06 Selvita Sa Novel benzimidazole derivatives as kinase inhibitors
US20150376198A1 (en) 2013-02-18 2015-12-31 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
CA2905418C (fr) 2013-03-13 2023-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Procedes de modulation de la cytotoxicite chimiotherapeutique
KR102307566B1 (ko) 2013-06-21 2021-10-05 제니쓰 에피제네틱스 리미티드 신규한 바이사이클릭 브로모도메인 억제제
US9828348B2 (en) 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
RU2732416C2 (ru) 2014-07-31 2020-09-16 Институт Пастер Корея Производные 2-амино-бензимидазола и их использование в качестве ингибиторов 5-липоксигеназы и/или простагландин е-синтазы
WO2016168660A1 (fr) 2015-04-17 2016-10-20 Forma Therapeutics, Inc. Tétralines de 3-spiro-7-acide hydroxamique en tant qu'inhibiteurs de hdac
WO2017052394A1 (fr) 2015-09-23 2017-03-30 Uniwersytet Jagielloński Composés d'imidazopyridine et leur utilisation comme ligands du récepteur 5-ht6
WO2017060488A1 (fr) 2015-10-09 2017-04-13 Almirall, S.A. Nouveaux antagonistes de trpa1
WO2017064068A1 (fr) 2015-10-14 2017-04-20 Almirall, S.A. Nouveaux antagonistes de trpa1
GB201603311D0 (en) 2016-02-25 2016-04-13 Jakobsson Per Johan New uses and methods
WO2018039384A1 (fr) 2016-08-23 2018-03-01 Ardelyx, Inc. Composés d'isoxazolyl-carbonyloxy azabicyclo [3.2.1] octane en tant qu'activateurs de fxr
US10501421B1 (en) * 2017-01-27 2019-12-10 Vanderbilt University Substituted benzimidazoles as modulators of Ras signaling

Also Published As

Publication number Publication date
AU2018351059B2 (en) 2022-05-12
CO2020004669A2 (es) 2020-05-05
CL2020001020A1 (es) 2020-09-21
EP3697410B1 (fr) 2024-12-18
CA3079081A1 (fr) 2019-04-25
ZA202002762B (en) 2025-03-26
SA520411787B1 (ar) 2022-08-29
EP3697410A1 (fr) 2020-08-26
EP3697410C0 (fr) 2024-12-18
JP2021500332A (ja) 2021-01-07
TWI816704B (zh) 2023-10-01
AU2018351059A1 (en) 2020-04-23
IL273839A (en) 2020-05-31
NZ763311A (en) 2026-03-27
HUE070649T2 (hu) 2025-06-28
US20200308145A1 (en) 2020-10-01
KR102697255B1 (ko) 2024-08-23
SG11202003502VA (en) 2020-05-28
WO2019079578A1 (fr) 2019-04-25
BR112020007589A2 (pt) 2020-09-24
EP3697410A4 (fr) 2021-08-11
MX2020003993A (es) 2020-08-13
IL273839B (en) 2022-09-01
US11332459B2 (en) 2022-05-17
ES3004333T3 (en) 2025-03-12
UY37941A (es) 2019-04-30
JP7450534B2 (ja) 2024-03-15
PL3697410T3 (pl) 2025-04-07
TW201930284A (zh) 2019-08-01
CN111417394B (zh) 2023-11-07
PH12020550265A1 (en) 2021-03-01
CN111417394A (zh) 2020-07-14
KR20200074965A (ko) 2020-06-25
BR112020007589A8 (pt) 2022-08-02
HRP20250272T1 (hr) 2025-04-25

Similar Documents

Publication Publication Date Title
EP3706762A4 (fr) N4-hydroxycytidine et dérivés et leurs utilisations anti-virales
MA52483A (fr) Dérivés de gip et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
MA50256A (fr) Composés de pyrazolopyrimidinone et leurs utilisations
EP3694861A4 (fr) Composés hétérocycliques et leurs utilisations
EP3788055A4 (fr) Dérivés de neurostéroïdes et leurs utilisations
EP3600273A4 (fr) Inhibiteurs de cd73 et leurs utilisations
EP3313530A4 (fr) Dérivés de 4,6-pyrimidinylène et utilisations de ceux-ci
EP3841096A4 (fr) Dérivés de pyridinylméthylènepipéridine et leurs utilisations
EP3697410A4 (fr) Dérivés de benzimidazole et leurs utilisations
EP3559000A4 (fr) Dérivés de benzimidazole, leurs procédés de préparation et leurs utilisations
EP3236972A4 (fr) N4-hydroxycytidine, ses dérivés et utilisations anti-virales
EP3297637A4 (fr) Dérivés de benzène-1,3,5-tricarboxamide et utilisations de ces dérivés
EP3624797A4 (fr) Inhibiteurs de kinase et leurs utilisations
EP2967046A4 (fr) Derives de benzimidazole et leurs utilisations
EP3526215A4 (fr) Dérivés de n-acyléthanolamide et leurs utilisations
EP3323817A4 (fr) Dérivés d'aniline pyrimidine et leurs utilisations
EP3347021A4 (fr) Cyano-thiénotriazoloazépines et leurs utilisations
MA46901A (fr) Agents psychotropes et leurs utilisations
EP3630154A4 (fr) Dérivés clivables de lipo-glycopeptides et leurs utilisations
EP3347006A4 (fr) Analogues deutérés d'étifoxine, leurs dérivés et leurs utilisations
EP3370771A4 (fr) Conjugués anti-cd3-folate et leurs utilisations
EP3303366A4 (fr) Dérivés de dolastatine 10 et utilisations de ceux-ci
EP3535243A4 (fr) Dérivés hétérocycliques tricycliques et leurs utilisations
MA46945A (fr) Exopolysaccharides et leurs utilisations